Ask AI
TROP2 and TIGIT in Lung Cancer

CE / CME

Conference to Clinic Roundtable: Applying the Latest Data Developments for Therapies Targeting TROP-2 and TIGIT in Lung Cancer

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Released: June 11, 2025

Expiration: December 10, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Based on Cohorts C and D in the EVOKE-02 trial, which statement best describes the clinical activity of sacituzumab govitecan + pembrolizumab + carboplatin in treatment-naive patients with metastatic NSCLC?

2.

Based on current clinical trial evidence, which of the following biomarkers is most consistently associated with potential benefit from TIGIT inhibitor combinations in patients with NSCLC?

3.

How confident are you in your ability to identify patients with advanced lung cancer who are eligible for enrollment in trials involving TROP-2– or TIGIT-targeted therapies?